Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39 (Q54878197)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39 |
scientific article |
Statements
1 reference
Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39 (English)
1 reference
Tomoya Mita
1 reference
Naoto Katakami
1 reference
Hidenori Yoshii
1 reference
Tomio Onuma
1 reference
Hideaki Kaneto
1 reference
Takeshi Osonoi
1 reference
Toshihiko Shiraiwa
1 reference
Keisuke Kosugi
1 reference
Yutaka Umayahara
1 reference
Tsunehiko Yamamoto
1 reference
Hiroki Yokoyama
1 reference
Nobuichi Kuribayashi
1 reference
Hideaki Jinnouchi
1 reference
Masahiko Gosho
1 reference
Iichiro Shimomura
1 reference
Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial
1 reference
18 April 2017
1 reference
40
1 reference
6
1 reference
808
1 reference
Identifiers
1 reference